2025 Global Guideline for the Diagnosis and Management of Candidiasis: Interpretation of Core Points for Oral Clinical Practice

doi:10.13701/j.cnki.kqyxyj.2026.03.001

Abstract

Abstract: The European Confederation for Medical Mycology, the International Society of Human and Animal Mycology, and the American Society for Microbiology jointly issued Global Guideline for the Diagnosis and Management of Candidiasis in February 2025. Based on high-quality evidence and expert consensus, this guideline systematically elaborates optimal strategies for diagnosing and managing candidiasis, with core contents including: risk stratification and sex-based differences, updates in etiology and species distribution shifts, multidimensional analysis of clinical manifestations, tiered recommendations for diagnostic techniques, stepwise disease management pathways, and graded prevention and control strategies. This article provides an in-depth interpretation of key aspects related to oral candidiasis within the guideline, integrating recent research advances for analysis and discussion. We aim to deliver evidence-based clinical guidance for oral healthcare practitioners and advance the standardization of diagnosis and treatment standards for oral candidiasis in China.

Key words: Candidiasis, oral, guideline, diagnostic and therapeutic standards, interpretation

LIU Zhiying, YANG Jin, ZHOU Hongmei. 2025 Global Guideline for the Diagnosis and Management of Candidiasis: Interpretation of Core Points for Oral Clinical Practice[J]. Journal of Oral Science Research, 2026, 42(3): 179-185.

References

[1] Denning DW. Global incidence and mortality of severe fungal disease[J]. Lancet Infect Dis, 2024, 24(7): e428-e438.
[2] Cornely OA, Sprute R, Bassetti M, et al. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM[J]. Lancet Infect Dis, 2025, 25(5): e280-e293.
[3] Stoopler ET, Villa A, Bindakhil M, et al. Common oral conditions: a review[J]. JAMA, 2024, 331(12): 1045-1054.
[4] Cifaldi C, Ursu GM, D'Alba I, et al. Main human inborn errors of immunity leading to fungal infections[J]. Clin Microbiol Infect, 2022, 28(11): 1435-1440.
[5] Jing D, Liang G, Li X, et al. Progress in molecular diagnosis and treatment of chronic mucocutaneous candidiasis[J]. Front Immunol, 2024, 15: 1343138.
[6] Chahine A, Farooqi S, Marzvanyan A, et al. Mucocutaneous Candida infections in immunocompromised patients[J]. Curr Dermatol Rep, 2022, 11(2): 73-88.
[7] He Y, Tang R, Deng J, et al. Effects of oestrogen on vulvovaginal candidosis[J]. Mycoses, 2022, 65(1): 4-12.
[8] Egger M, Hoenigl M, Thompson GR, et al. Let's talk about sex characteristics-As a risk factor for invasive fungal diseases[J]. Mycoses, 2022, 65(6): 599-612.
[9] Loster JE, Wieczorek A, Loster BW. Correlation between age and gender in Candida species infections of complete denture wearers: a retrospective analysis[J]. Clin Interv Aging, 2016, 11: 1707-1714.
[10] Aminzadeh A, Sabeti Sanat A, Nik Akhtar S. Frequency of candidiasis and colonization of Candida albicans in relation to oral contraceptive pills[J]. Iran Red Crescent Med J, 2016, 18(10): e38909.
[11] Liu F, Hu ZD, Zhao XM, et al. Phylogenomic analysis of the Candida auris-Candida haemuli clade and related taxa in the Metschnikowiaceae, and proposal of thirteen new genera, fifty-five new combinations and nine new species[J]. Persoonia, 2024, 52: 22-43.
[12] de Hoog S, Walsh TJ, Ahmed SA, et al. A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC[J]. J Clin Microbiol, 2023, 61(11): e0087323.
[13] Kidd SE, Abdolrasouli A, Hagen F. Fungal nomenclature: managing change is the name of the game[J]. Open Forum Infect Dis, 2023, 10(1): ofac559.
[14] Hu L, He C, Zhao C, et al. Characterization of oral candidiasis and the Candida species profile in patients with oral mucosal diseases[J]. Microb Pathog, 2019, 134: 103575.
[15] Bose D, Brizuela M. Fungal infections of the oral mucosa[M]//StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025.
[16] Xiao M, Chen SC, Kong F, et al. Distribution and antifungal susceptibility of Candida species causing candidemia in China: an update from the CHIF-NET study[J]. J Infect Dis, 2020, 221(Suppl 2): S139-S147.
[17] Burki T. WHO publish fungal priority pathogens list[J]. Lancet Microbe, 2023, 4(2): e74.
[18] Alfaifi A, Brooks JK, Jabra-Rizk MA, et al. Does Candida auris colonize the oral cavity? A retrospective institutional experience[J]. Oral Dis, 2023, 30(4): 2716-2718.
[19] Siripaisanprasert K, Prapinjumrune C, Changsiripun C. Oral Candida in orthodontic patients wearing removable orthodontic appliances: a systematic review and meta-analysis[J]. Int Dent J, 2025, 75(5): 100905.
[20] Bing J, Huang Y, Du H, et al. Rapid spread of Candida auris in China after COVID-19[J]. J Infect, 2025, 90(4): 106476.
[21] 全国医疗机构感染监测网,中华预防医学会医院感染控制分会,全国医院感染监控管理培训基地. 耳念珠菌医院感染预防与控制专家共识[J].中华医学杂志,2025,105(23): 1907-1917.
[22] 周红梅,周刚,周威,等.口腔黏膜病药物治疗精解[M].第2版. 北京: 人民卫生出版社, 2024: 16-18.
[23] 浙江省性病艾滋病防治协会艾滋病临床治疗专业委员会,浙江省性病艾滋病防治协会艾滋病护理和关怀专业委员会.HIV感染者口咽念珠菌病管理专家共识[J].中华临床感染病杂志,2023,16(2): 108-112.
[24] Vila T, Sultan AS, Montelongo-Jauregui D, et al. Oral candidiasis: a disease of opportunity[J]. J Fungi (Basel), 2020, 6(1): 15.
[25] G M, Ravi SSS, Maheswary D, et al. Role of Candida albicans in chronic inflammation and the development of oral squamous cell carcinoma[J]. Cancer Pathog Ther, 2025, 3(5): 402-410.
[26] 国家卫生健康委办公厅.国家卫生健康委办公厅关于印发口腔相关病种诊疗指南(2022年版)的通知[S/OL].(2022-09-30)[2025-07-12].
[27] 中国成人念珠菌病诊断与治疗专家共识组.中国成人念珠菌病诊断与治疗专家共识[J].中华传染病杂志,2020,38(1): 29-43.
[28] 杨淼,周红梅.口腔念珠菌病的微生物学诊断理念和椅旁镜检的价值分析[J].口腔医学研究,2021,37(7): 588-591.
[29] Jensen HE. Histopathology in the diagnosis of invasive fungal diseases[J]. Curr Fungal Infect Rep, 2021, 15(1): 23-31.
[30] Evren E, Göçmen JS, İştar EH, et al. Medically important Candida spp. identification: an era beyond traditional methods[J]. Turk J Med Sci, 2022, 52(3): 834-840.
[31] Arastehfar A, Daneshnia F, Kord M, et al. Corrigendum: comparison of 21-plex PCR and API 20C AUX, MALDI-TOF MS, and rDNA sequencing for a wide range of clinically isolated yeast species: improved identification by combining 21-plex PCR and API 20C AUX as an alternative strategy for developing countries[J]. Front Cell Infect Microbiol, 2019, 9: 176.
[32] Fang W, Wu J, Cheng M, et al. Diagnosis of invasive fungal infections: challenges and recent developments[J]. J Biomed Sci, 2023, 30(1): 42.
[33] Kwizera R, Abdolrasouli A, Garcia-Effron G, et al. Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings[J]. Lancet Infect Dis, 2024, 24(12): e782-e793.
[34] Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 62(4): e1-e50.
[35] Zhang Z, Zhang X, Zhou YY, et al. The safety of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis[J]. BJOG, 2019, 126(13): 1546-1552.
[36] Alexander BD, Cornely O, Pappas P, et al. Efficacy and safety of oral ibrexafungerp in 41 patients with refractory fungal diseases, interim analysis of a phase 3 open-label study (FURI)[J]. Open Forum Infect Dis, 2020, 7(suppl 1): S642.